Biotech Gainers: MannKind Corporation (NASDAQ:MNKD), Celldex Therapeutics (NASDAQ:CLDX), Dendreon Corporation (NASDAQ:DNDN), Intrexon Corp (NYSE:XON)



MannKind Corp. (NASDAQ: MNKD) was raised to Neutral from Underweight by Piper Jaffray. MannKind Corporation (NASDAQ:MNKD) stock performance was 6.53% in last session and finished the day at $7.01. Traded volume was 16.68million shares in the last session and the average volume of the stock remained 10.11million shares. The beta of the stock remained 1.40. MannKind Corporation (NASDAQ:MNKD) insider ownership is 0.30%.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that data from its Phase 1 study of varlilumab, a fully human monoclonal antibody targeting CD27, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 in Chicago. The abstracts accepted for poster presentation are listed below. Celldex Therapeutics, Inc. (NASDAQ:CLDX) rose 26.94 percent to $15.74 Wednesday on volume of 9.27million shares. The intra-day range of the stock was $12.85 to $15.97. Celldex Therapeutics, Inc. (NASDAQ:CLDX) has a market capitalization of $1.41billion.

To fulfill a post marketing requirement and as a part of the company’s ongoing commitment to patients, Dendreon Corporation (NASDAQ:DNDN) will conduct a registry of approximately 1,500 patients to further evaluate a small potential safety signal of cerebrovascular events. In four randomized clinical trials of PROVENGE in prostate cancer patients, cerebrovascular events were observed in 3.5% of patients in the PROVENGE group compared with 2.6% of patients in the control group. Dendreon Corporation (NASDAQ:DNDN)’s stock on May 14, 2014 reported a increase of 5.37% to the closing price of $2.16. Its fifty two weeks range is $1.81 -$5.38. The total market capitalization recorded $345.72million. The overall volume in the last trading session was 2.86million shares. In its share capital, DNDN has 159.95million outstanding shares.

Intrexon Corp (NYSE:XON) Insider Donald Lehr bought 1,850 shares of the stock in a transaction that occurred on Tuesday, May 13th. The shares were purchased at an average cost of $15.99 per share, for a total transaction of $29,581.50. Following the completion of the transaction, the insider now directly owns 15,326 shares of the company’s stock, valued at approximately $245,063. On Wednesday, shares of Intrexon Corp (NYSE:XON) advanced 12.84% to close the day at $17.49. Company return on investment (ROI) is -15.70% and its monthly performance is recorded as -13.88%. Intrexon Corp (NYSE:XON) quarterly revenue growth is -38.20%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone